Hongzhen WANG, Kaixin ZHANG, Liang MA, Yingjie YU
Eurasian Journal of Medicine and Oncology - 2026;10(4):1-7
Prostate cancer is one of the most common malignant tumors in men worldwide. Its pathogenesis is complex and involves the abnormal regulation of multiple genes and signaling pathways. Non-SMC condensin II complex subunit D3 (NCAPD3), a core component of the condensin II complex, was initially identified as being primarily involved in chromosome condensation and segregation during mitosis and in maintaining genomic stability. In recent years, advances in research on the molecular mechanisms of tumors have increasingly revealed the aberrant expression and oncogenice role of NCAPD3 in prostate cancer and other malignancies, suggesting that NCAPD3 may represent a potential target for molecularly targeted therapy in prostate cancer. Based on the existing evidence, this article reviews the biological functions, expression characteristics, associations with clinicopathological characteristics and prognosis, regulatory mechanisms, and potential clinical applications of NCAPD3 in prostate cancer.
